Mirzotamab

Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclaxum (HY-137774), an BCL2L1 inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC).
Read more
€0.00 (tax incl.)
Reference:
HY-P99740
Product Details
HY-P99740

Data sheet

Size
Multiple sizes
Reactivity
ADC Antibody
Application
Cancer-programmed cell death
CAS
2229859-11-2

Menu

Settings